Parkman Healthcare Partners LLC Has $18.87 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Parkman Healthcare Partners LLC increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 16.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 755,244 shares of the company’s stock after acquiring an additional 108,102 shares during the period. Kiniksa Pharmaceuticals comprises approximately 2.4% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 9th largest holding. Parkman Healthcare Partners LLC owned 1.05% of Kiniksa Pharmaceuticals worth $18,874,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after purchasing an additional 157,741 shares during the last quarter. Segall Bryant & Hamill LLC bought a new position in Kiniksa Pharmaceuticals during the third quarter worth about $675,000. Millennium Management LLC increased its position in Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals in the third quarter valued at approximately $2,438,000. Finally, Semanteon Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $551,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This represents a 13.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Price Performance

KNSA stock opened at $21.17 on Wednesday. The business’s fifty day moving average price is $23.83 and its two-hundred day moving average price is $23.00. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -151.20 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.47 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same period in the prior year, the business posted ($0.20) earnings per share. Kiniksa Pharmaceuticals’s revenue was up 67.4% compared to the same quarter last year. Research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KNSA. Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.